Corneal topography important to monitor after CXL

Article

When performing corneal collagen crosslinking (CXL), ophthalmologists should monitor the keratoconus index and the index of height asymmetry garnered from the Scheimpflug camera, because changes in values of these indices are independent from initial corneal thickness.

When performing corneal collagen crosslinking (CXL), ophthalmologists should monitor the keratoconus index and the index of height asymmetry garnered from the Scheimpflug camera, because changes in values of these indices are independent from initial corneal thickness. So say researchers from Hungary publishing their work in the Journal of Refractive Surgery.

The researchers, from Hungary, performed CXL in 25 eyes with progressive keratoconus; 25 fellow eyes with nonprogressive keratoconus were the control subjects. The Scheimpflug camera was used to measure thinnest corneal thickness, anterior keratometry (flat, steep) and keratoconus indices before and after CXL (at 12 to 25 months). They assessed the influence of corneal thickness and follow-up time on the flattening effect of CXL using regression analysis.

The investigators found that, at baseline, the eyes that had undergone CXL had significantly higher steep keratometric values and lower thinnest corneal thickness values. These findings were parallel with increased values of the following keratoconus indices: index of surface variance, index of vertical asymmetry, keratoconus index, centre keratoconus index, index of height asymmetry, index of height decentration and radius minimum.

After they adjusted for thinnest corneal thickness and follow-up time, the researchers found that a significant flattening effect was shown with CXL; it was expressed by changes in radius minimum, index of surface variance, keratoconus index, center keratoconus index and index of height asymmetry. Changes of index of surface variance, index of vertical asymmetry and center keratoconus index were significantly influenced by thinnest corneal thickness. Follow-up time had no significant influence in any of the models studied.

To read an abstract of the study, visit the journal's website.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.